NCT04360512

Brief Summary

Ankle mobility limitations are common in older adults. A possible treatment to restore joint mobility is manual therapy based on mobilization techniques, in this case, applied on the ankle joint. Previous research had proposed different treatment volumes (one to twelve sessions), but shown a different and non-consistent degree of effectiveness according to such factor. Therefore, this work aims to determine the dose-response relationship of manual therapy (talus mobilizations) on ankle range of motion in the older adult. Secondarily, this research will appraise whether a likely improvement in ankle mobility may have an impact on the overall mobility (i.e. gait, get up from a chair).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 18, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 24, 2020

Completed
21 days until next milestone

Study Start

First participant enrolled

May 15, 2020

Completed
14 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 29, 2020

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 14, 2020

Completed
Last Updated

September 16, 2020

Status Verified

September 1, 2020

Enrollment Period

14 days

First QC Date

April 18, 2020

Last Update Submit

September 14, 2020

Conditions

Keywords

ROMManual therapyDose-responseMobilizationAnkle

Outcome Measures

Primary Outcomes (1)

  • Treatment dose

    Number of sessions of experimental intervention needed to induce a clinically important gain in ankle mobility after the intervention. A baseline progression over 4.6º in the Lunge test will be considered clinically important (Powden, 2015), so that the number of sessions will be established when this threshold is exceeded (see secondary outcome) .

    Change from baseline to end of intervention (2 weeks)

Secondary Outcomes (3)

  • The Lunge test

    Change from baseline, to end of intervention (2 weeks) and follow-up (10 weeks)

  • Active ankle range of motion

    Change from baseline, to end of intervention (2 weeks) and follow-up (10 weeks)

  • Timed up and go test (TUG)

    Change from baseline, to end of intervention (2 weeks) and follow-up (10 weeks)

Other Outcomes (1)

  • Euro Quality of Life Five Dimensions (EQ-5D)

    Change from baseline, to follow-up (10 weeks)

Study Arms (4)

One session

EXPERIMENTAL

One session of talus posteriorization

Procedure: Posteriorization of the talus

Two sessions

EXPERIMENTAL

Two sessions of talus posteriorization

Procedure: Posteriorization of the talus

Three sessions

EXPERIMENTAL

Three sessions of talus posteriorization

Procedure: Posteriorization of the talus

Four sessions

EXPERIMENTAL

Four sessions of talus posteriorization

Procedure: Posteriorization of the talus

Interventions

Three sets of a 30-s grade IV mobilization

Four sessionsOne sessionThree sessionsTwo sessions

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Community-dwelling older adults
  • Over 60 years
  • Limited ankle dorsiflexion range of motion

You may not qualify if:

  • Not willing to participate or signing a consent form
  • Lower limb injury in the three months prior to the study (ex. sprain)
  • Diagnosed condition that may influence mobility assessments (i.e. stroke)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universidad de Valencia

Valencia, 46010, Spain

Location

Study Officials

  • José-María Blasco, PT, PhD

    University of Valencia

    STUDY DIRECTOR
  • David Hernández-Guillén, PT, PhD

    University of Valencia

    STUDY CHAIR
  • Catalina Tolsada-Velasco, PT

    University of Valencia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PT, PhD

Study Record Dates

First Submitted

April 18, 2020

First Posted

April 24, 2020

Study Start

May 15, 2020

Primary Completion

May 29, 2020

Study Completion

September 14, 2020

Last Updated

September 16, 2020

Record last verified: 2020-09

Locations